BioVaxys Technology Corp.
BioVaxys is a clinical-stage biotechnology company based in Vancouver, developing viral and oncology vaccine platforms, immuno-diagnostics, and advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine. The company is engaged in research collaborations, vaccine development, and bio-production partnerships, with a focus on creating durable and broad-spectrum vaccines against major viral threats.
Industries
Nr. of Employees
small (1-50)
BioVaxys Technology Corp.
146 Thirtieth Street, Suite 100, Etobicoke, Ontario, Canada
Patents
Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
US-12042537-B2
View Details
Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
US-12042537-B2
View DetailsProducts
Pan-sarbecovirus vaccine candidate (booster formulation)
A vaccine candidate designed as a booster administered with existing SARS-CoV-2 vaccines to elicit cross-reactive neutralizing antibodies against SARS-CoV-2 variants and related sarbecoviruses.
Haptenized autologous cell cancer vaccine (clinical-stage candidate)
Autologous cell-based vaccine platform using chemically modified (haptenized) patient-derived cells for oncology applications, intended for use with immune checkpoint inhibitors.
T-cell immune response diagnostic
A diagnostic assay intended to detect T-cell mediated immune responses to viral antigens, used to evaluate cellular immunity to SARS-CoV-2.
Pan-sarbecovirus vaccine candidate (booster formulation)
A vaccine candidate designed as a booster administered with existing SARS-CoV-2 vaccines to elicit cross-reactive neutralizing antibodies against SARS-CoV-2 variants and related sarbecoviruses.
Haptenized autologous cell cancer vaccine (clinical-stage candidate)
Autologous cell-based vaccine platform using chemically modified (haptenized) patient-derived cells for oncology applications, intended for use with immune checkpoint inhibitors.
T-cell immune response diagnostic
A diagnostic assay intended to detect T-cell mediated immune responses to viral antigens, used to evaluate cellular immunity to SARS-CoV-2.
Services
Collaborative execution of preclinical vaccine studies, including assay development, animal immunizations, and neutralizing antibody endpoint analysis.
Provision of clinical-grade vaccine manufacturing through contract-manufacturing partnerships and partner-managed GMP facility construction and operation.
Development and validation of diagnostic assays to detect T-cell mediated immune responses to viral antigens.
Collaborative execution of preclinical vaccine studies, including assay development, animal immunizations, and neutralizing antibody endpoint analysis.
Provision of clinical-grade vaccine manufacturing through contract-manufacturing partnerships and partner-managed GMP facility construction and operation.
Development and validation of diagnostic assays to detect T-cell mediated immune responses to viral antigens.
Expertise Areas
- Vaccine research and preclinical development
- Oncology immunotherapy and autologous cell vaccines
- Biomanufacturing for clinical supply (GMP)
- Immunodiagnostics development
Key Technologies
- Haptenized viral protein vaccines
- Depot/controlled-release formulation platform
- Recombinant protein expression and purification
- Surrogate virus neutralization assays
News & Updates
The Ohio State University completed preparation of surrogate virus neutralization assays for SARS-CoV-2 variants and other sarbecoviruses, advancing the research collaboration with BioVaxys.
BioVaxys reported a 96.4% positive antibody immune response in a murine model study of its SARS-CoV-2 vaccine candidate.
BioVaxys partnered with BioElpida to construct a GMP facility for producing clinical supply of an ovarian cancer vaccine.
The WHO highlights the critical need for broad-spectrum vaccines due to evolving variants and waning booster responses.
BioVaxys received patent allowance for its DPX formulation in Japan, expanding its intellectual property portfolio.
The Ohio State University completed preparation of surrogate virus neutralization assays for SARS-CoV-2 variants and other sarbecoviruses, advancing the research collaboration with BioVaxys.
BioVaxys reported a 96.4% positive antibody immune response in a murine model study of its SARS-CoV-2 vaccine candidate.
BioVaxys partnered with BioElpida to construct a GMP facility for producing clinical supply of an ovarian cancer vaccine.
The WHO highlights the critical need for broad-spectrum vaccines due to evolving variants and waning booster responses.
BioVaxys received patent allowance for its DPX formulation in Japan, expanding its intellectual property portfolio.